Navigation Links
New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
Date:10/24/2007

Study Confirms Role of AMBIEN CR in Effectively Managing Insomnia to

Improve Quantity and Quality of Work Performance

BRIDGEWATER, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results from a new study that showed patients with chronic insomnia who were treated with 12.5 mg of AMBIEN CR(R) (zolpidem tartrate extended- release) tablets CIV experienced significant improvements in two key parameters of work performance - output and time management - over a period of 12 weeks compared with patients taking placebo. Patients with chronic insomnia can have a higher frequency of work-related problems including absenteeism, an increased rate of accidents, difficulty performing duties and less job satisfaction. These results, which were part of a larger study that evaluated the efficacy and safety of AMBIEN CR when taken as needed, were recently presented at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida.

The multi-center, phase IIIb, randomized, double-blind study included 728 patients with chronic primary insomnia (478 treated with AMBIEN CR and 250 treated with placebo). Treatment with AMBIEN CR showed significantly higher improvement from baseline in work tasks at week 12 in Work Limitation Questionnaire (WLQ) for both Time Management Scale (- 7.39 difference; p < 0.001) and the Output Scale (- 4.8 difference; p = 0.0076) compared to placebo, which was confirmed by an effect size analysis. The majority of adverse events experienced by patients in the study were mild to moderate in intensity, and the most frequently reported adverse events by participants include headache, anxiety and somnolence.

"These new data add to the growing body of evidence that shows that the treatment of chronic insomnia can improve next day functioning," said Milton Erman, MD, chief medical officer, Avastra USA, and clinical professor of psychiatry, UCSD School of Medicine. "This study demonstrates
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)...  In a policy paper released ... largest lesbian, gay, bisexual and transgender (LGBT) civil ... for Pre-Exposure Prophylaxis (PrEP). PrEP is any medical ... spread of a disease or infection prior to ... drug combination currently approved for PrEP, which protects ...
(Date:10/17/2014)...  Amgen (NASDAQ: AMGN ) today announced ... president of Gladstone Institutes and Gladstone,s Robert W. and ... are pleased to welcome Dr. Sandy Williams ... , chairman and chief executive officer of Amgen. "Dr. ... his direct experience in our industry will both be ...
(Date:10/17/2014)... 2014 According to ... Technique (Optical Coherence Tomography, Hyperspectral Imaging, Photoacoustic ... Neurology, Oncology, Cardiology) - Global Forecasts to ... Optical Imaging market over the forecast period ... $917.1 million in 2014 and is expected ...
Breaking Medicine Technology:HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Zereana Jess-Huff, a ... Mrs. Maryland 2014 on a platform to think outside the ... and uses her position to raise awareness about women’s other ... for breast cancer. You say the color pink and everybody ... know for a fact that it has not been won ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... A new report released Wednesday,February 11, 2009 by ... physical activity, Special Olympics athletes are more physically active,than ... , U.S. Vice President Joe ... Winter Games in Boise, Idaho on Thursday, February 12, ...
... Virtua Health has responded to the public regarding legal action ... Court judge ordered Virtua to stop its Top Doc advertising ... advertising statements are fraudulent. Cooper also sent an e-mail to ... "Virtua has always had the highest ethical standards and ...
... , ... Eagan, MN (Vocus) February 11, 2009 -- Employees of DeCare ... Northeastern Minnesota. A company cookbook was created and recipes were gathered ... than 200 cookbooks were sold. , , , , ,"After years ...
... Feb. 11 Cogdell Spencer Inc. (NYSE:, CSA ... of the Northwest,Region for the Company,s wholly owned subsidiary, ... Based in the Company,s Seattle office, Mr. Aigner ... be responsible for all,design-build and development projects in the ...
... with salivary gland , , WEDNESDAY, Feb. 11 (HealthDay News) -- A ... who blew his tuba so hard that he sent air into ... the condition after the boy developed swelling and pain around his ... Deepa Mukundan, who wrote about the case in the Feb. 12 ...
... ("Transition" or the "Company") (TSX: TTH; NASDAQ: ... disease indications with large markets, today announced its financial ... Selected Highlights, -------------------, ... and up to the date of this press,release, the ...
Cached Medicine News:Health News:Special Olympics Issues Report on the Impact of Special Olympics Healthy Athletes Initiative to show Need for Reauthorization of the Special Olympics Sport and Empowerment Act of 2004 2Health News:Special Olympics Issues Report on the Impact of Special Olympics Healthy Athletes Initiative to show Need for Reauthorization of the Special Olympics Sport and Empowerment Act of 2004 3Health News:Virtua Health Responds to Court Order 2Health News:Company Cookbook Proceeds to Benefit United Way of Northeastern Minnesota 2Health News:Cogdell Spencer Announces Aigner as President in the Northwest Region 2Health News:Cogdell Spencer Announces Aigner as President in the Northwest Region 3Health News:Tuba Spells Trouble for Young Musician 2Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 2Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 3Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 4Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 5Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 6Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 7Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 8Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 9Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 10Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 11Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 12Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 13Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 14Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 15
... the first and only one-bottle lens care ... conditions gas permeable contact lenses, but also ... the leading two-bottle GP lens care system. ... insertion by enveloping the lenses and creating ...
Menicon Z is a rigid gas lens with high oxygen permeability. As one of its specific characteristics, it can provide superior visual correction and show excellent performance against astigmatism....
... using sophisticated lathing techniques, intrinsically permeable polymers ... a center thickness of just 0.08 across ... powered Thinsite lenses maintain a 30% decrease ... unique design eliminates stress points to reduce ...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: